Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Smoker characteristics and smoking-cessation milestones.

Japuntich SJ, Leventhal AM, Piper ME, Bolt DM, Roberts LJ, Fiore MC, Baker TB.

Am J Prev Med. 2011 Mar;40(3):286-94. doi: 10.1016/j.amepre.2010.11.016.

2.

The effect of five smoking cessation pharmacotherapies on smoking cessation milestones.

Japuntich SJ, Piper ME, Leventhal AM, Bolt DM, Baker TB.

J Consult Clin Psychol. 2011 Feb;79(1):34-42. doi: 10.1037/a0022154.

3.

Using ecological measures of smoking trigger exposure to predict smoking cessation milestones.

Minami H, Tran LT, McCarthy DE.

Psychol Addict Behav. 2015 Mar;29(1):122-8. doi: 10.1037/adb0000017. Epub 2014 Aug 18.

4.

Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study.

Kalman D, Herz L, Monti P, Kahler CW, Mooney M, Rodrigues S, O'Connor K.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):111-8. doi: 10.1016/j.drugalcdep.2011.03.005. Epub 2011 Apr 19.

5.

Isolating the role of psychological dysfunction in smoking cessation: relations of personality and psychopathology to attaining cessation milestones.

Leventhal AM, Japuntich SJ, Piper ME, Jorenby DE, Schlam TR, Baker TB.

Psychol Addict Behav. 2012 Dec;26(4):838-49. doi: 10.1037/a0028449. Epub 2012 May 28.

6.

Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.

Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G.

Addiction. 2004 Sep;99(9):1206-18.

PMID:
15317642
7.

Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers.

Shiffman S, Scharf DM, Shadel WG, Gwaltney CJ, Dang Q, Paton SM, Clark DB.

J Consult Clin Psychol. 2006 Apr;74(2):276-85.

PMID:
16649872
8.

Paths to tobacco abstinence: A repeated-measures latent class analysis.

McCarthy DE, Ebssa L, Witkiewitz K, Shiffman S.

J Consult Clin Psychol. 2015 Aug;83(4):696-708. doi: 10.1037/ccp0000017. Epub 2015 Apr 13.

9.

Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention.

Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, Rowland KM, Bernath A, Loots ML, Le-Lindqwister NA, Tschetter LK, Garneau SC, Flynn KA, Ebbert LP, Wender DB, Loprinzi CL.

Mayo Clin Proc. 2007 Feb;82(2):186-95.

PMID:
17290726
10.

Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokers.

Nakamura M, Oshima A, Ohkura M, Arteaga C, Suwa K.

Clin Ther. 2014 Jun 1;36(6):918-27. doi: 10.1016/j.clinthera.2014.03.013. Epub 2014 May 5.

11.

Relapse dynamics during smoking cessation: recurrent abstinence violation effects and lapse-relapse progression.

Kirchner TR, Shiffman S, Wileyto EP.

J Abnorm Psychol. 2012 Feb;121(1):187-97. doi: 10.1037/a0024451. Epub 2011 Jul 25.

13.

Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking.

Gariti P, Lynch K, Alterman A, Kampman K, Xie H, Varillo K.

J Subst Abuse Treat. 2009 Oct;37(3):247-55. doi: 10.1016/j.jsat.2009.01.006. Epub 2009 Mar 31.

14.

Systematic review and meta-analysis of combination therapy for smoking cessation.

Shah SD, Wilken LA, Winkler SR, Lin SJ.

J Am Pharm Assoc (2003). 2008 Sep-Oct;48(5):659-65. doi: 10.1331/JAPhA.2008.07063. Review.

PMID:
18826906
15.

[Smoking cessation after 12 months follow-up at a smoking cessation unit].

Pascual-Lledó JF, De la Cruz-Amorós E, Bustamante-Navarro R, Buades-Sánchez MR, Contreras-Santos C, Castillo-Aguilar C.

Med Clin (Barc). 2006 Apr 29;126(16):601-6. Spanish.

PMID:
16759550
16.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
17.

Pharmacotherapy for smoking cessation: current advances and research topics.

Raupach T, van Schayck CP.

CNS Drugs. 2011 May;25(5):371-82. doi: 10.2165/11590620-000000000-00000. Review.

PMID:
21476609
18.

Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.

King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, Kaprio J, Lerman C, Park PW.

Neuropsychopharmacology. 2012 Feb;37(3):641-50. doi: 10.1038/npp.2011.232. Epub 2011 Nov 2.

19.

Mechanisms of change in extended cognitive behavioral treatment for tobacco dependence.

Hendricks PS, Delucchi KL, Hall SM.

Drug Alcohol Depend. 2010 Jun 1;109(1-3):114-9. doi: 10.1016/j.drugalcdep.2009.12.021. Epub 2010 Jan 21.

20.

A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.

Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC.

J Clin Psychopharmacol. 2007 Aug;27(4):380-6.

PMID:
17632223

Supplemental Content

Support Center